DONATE

Towards a treatment for myotonic dystrophy: the first 3D model with patient cells

IBEC researchers led by Javier Ramón and Juan M. Fernández develop the first three-dimensional model for myotonic dystrophy, a rare disease that currently has no cure. The model combines patient cells and bioengineering techniques and represents a major advance over the use of animals and cell cultures. This new model will help in the design of personalized and more effective treatments, and for drug testing in a much more efficient way.

Observed in vivo the collective movement of nanorobots 

A team of researchers led by Samuel Sánchez from IBEC has monitored, for the first time, the behaviour of a swarm of nanorobots inside living mice. The study, published in the prestigious journal Science Robotics, reveals a coordinated movement, which could result in a very promising future in the field of precision medicine. 

IBEC researchers propose a cheaper and more ethical model for toxicological studies

A new study by IBEC’s Bacterial Infections: Antimicrobial Therapies and Molecular and cellular neurobiotechnology groups shows that Galleria mellonella larvae can be effective to test the toxicity of nanoparticles. This work thus paves the way toward a new animal model for toxicity studies that represent an inexpensive and more ethical alternative to rodent testing.

Willpower is the key to enhancing learning and memory: researchers uncover the mechanism

An international team led by the SPECS Laboratory at the IBEC has identified, for the first time in humans, the physiological mechanism responsible for the effectiveness of learning processes based on self-motivation and freedom of choice. The protagonists of this mechanism are theta-type brain waves, which regulate the ability of the human hippocampus to fix and retrieve information.